Elevation Oncology (NASDAQ:ELEV) Rating Lowered to “Neutral” at HC Wainwright
Elevation Oncology (NASDAQ:ELEV – Get Free Report) was downgraded by equities researchers at HC Wainwright from a “strong-buy” rating to a “neutral” rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. HC Wainwright also issued estimates for Elevation Oncology’s Q3 2026 earnings at ($0.11) EPS. Other equities research analysts have also […]
Elevation Oncology (NASDAQ:ELEV – Get Free Report) was downgraded by equities researchers at HC Wainwright from a “strong-buy” rating to a “neutral” rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. HC Wainwright also issued estimates for Elevation Oncology’s Q3 2026 earnings at ($0.11) EPS. Other equities research analysts have also […]
